Skip to content | Skip to institutional links

Common menu bar links

Publicly funded Immunization Programs in Canada - Routine Schedule for Infants and Children including special programs and catch-up programs (as of September 2011)

Information on immunization programs was collected by the Canadian Nursing Coalition on Immunization (CNCI). PHAC and the CNCI have worked together since July 2004 to develop this tool containing the latest provincial/territorial program information.

Province or Territory	DTaP-IPV-Hib	DTaP-IPV	Tdap or Tdap-IPV	HB	MMR	Var	MMRV	Men-C	Men-C-A, C, Y, W-135	Pneu-C-10	Pneu-C-13	Inf	HPV	Rot
Legend: DTaP: Diphtheria, Tetanus, Acellular Pertussis HB: Hepatitis B Hib: Haemophilus Influenzae Type b HPV: Human Papillomavirus Inf: Influenza IPV: Inactivated Poliomyelitis Men-C: Meningococcal conjugate MMR: Measles, Mumps, Rubella MMRV: Measles, Mumps, Rubella, and Varicella Pneu-C-7, Pneu-C-10, Pneu-C-13: Pneumococcal conjugate 7, 10, and 13 valent Pneu-P-23: Pneumococcal polysaccharide 23 valent Rot: Rotavirus Var: Varicella
Recommended use: 1. If meningococcal C conjugate vaccine is given to infants < 12 months of age, a booster dose should be given in the second year of life (from 12 to 23 months of age). The early adolescent dose may be given using either meningococcal C conjugate (Men-C) vaccine or quadrivalent conjugate meningococcal vaccine (Men-C-ACYW) depending on the burden of illness from serogroups A, Y and W135 and the age distribution of cases by serogroup in individual Provinces / territories. Updated Invasive Meningococcal Vaccine Conjugate Recommendations can be found at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf 2. The HPV vaccine is recommended for females between 9 and 13 years of age, as this is before the onset of sexual intercourse for most females in Canada, and the efficacy would be greatest. Females between the ages of 14 and 26 years would benefit from the HPV vaccine, even if they are already sexually active, as they may not yet have HPV infection and are very unlikely to have been infected with all four HPV types in the vaccine. Females between the ages of 14 and 26 years who have had previous Pap abnormalities, including cervical cancer, or have had genital warts or known HPV infection would still benefit from the HPV vaccine.
NACI recom- mendation	2, 4, 6, 18 mths	4-6 yrs	14-16 yrs	Infancy (3 doses) OR Pre-teen/teen (2-3 doses)	12 mths AND 18 mths OR 4-6 yrs	12-18 mths (1 dose)	12 mths AND 18 mths OR 4-6 yrs	Infancy (1-4 doses)¹ AND Pre-teen (1 dose)¹	Pre-teen (1 dose) ¹	2, 4, 6, 12-15 mths	2, 4, 6, 12-15 mths	6-23 mths (1-2 doses)	Females 9-13 yrs (3 doses at 0, 2, 6 mths)²	2, 4, 6 mths
BC	2, 4, 6 (DTaP- HB-IPV-Hib); 18 mths (DTaP-IPV-Hib)	4-6 yrs	Tdap, Gr. 9	2, 4, 6 mths (DTaP- HB-IPV-Hib); Catch-up Gr. 6 (HB)	12, 18 mths	12 mths, Catch-up 4-6 yrs, Gr. 6		2, 12 mths, Gr. 6			2, 4, (6 HR), 12 mths	6-23 mths	Females Gr. 6
AB	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	Gr. 5	4-6 yrs		12 mths	2, 4, 12 mths	Grade 9 (1 dose)		2, 4, (6 HR), 12 mths	≥ 6 mths	Females Gr. 5; Catch-up Gr. 9 in 2009-12
SK	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 8, contacts of infants	Gr. 6	Catch up Gr. 8, 12	Catch-up Gr. 6	12, 18 mths	12 mths, 4-6 yrs; Catch up Gr. 6	Starting in fall 2011 Gr. 6		2, 4, 6, 18 mths	6-59 mths	Females Gr. 6
MB	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs	Gr. 4	12 mths, 4-6 yrs	12 mths		12 mths; Catch-up Gr. 4			2, 4, 6, 18 mths	2011-12 ≥ 6 mths	Females Gr. 6
ON	2, 4, 6, 18 mths	4-6 yrs	Tdap, 14-16 yrs	Gr. 7	12 mths	15 mths; Catch-up 4-6 yrs	4-6 yrs	12 mths	Catch up starting Gr. 7		2, 4, (6 HR), 12 mths	≥ 6 mths	Females Gr. 8	2, 4 mths
QC	2, 4, 6, 18 mths		Tdap-IPV, 4-6 yrs; Tdap, 14-16 yrs	Gr. 4	18 mths		12 mths	12 mths; Catch-up < 18 yrs			2, 4, 12 mths	6-23 mths	Females Gr. 4 (2 doses), 3^rd year of high school (1 dose); Catch-up Females < 18 yrs
NB	2, 4, 6, 18 mths	4 yrs	Tdap, Gr. 9	0, 2, 6 mths	12, 18 mths; Catch-up Gr. 12 2007-12	12, 18 mths (children born in 2009 or later). One dose children born between 2000 and 2008	12, 18 mths; Catch-up children born in 2009	12 mths	Gr. 9		2, 4, 12 mths	6 mths – 18 yrs	Females Gr. 7
NS	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 7	Gr. 7	12 mths, 4-6 yrs	12 mths; Catch-up 1-12 yrs		12 mths; Catch-up Gr. 7			2, 4, 6, 18 mths	≥ 6 mths	Females Gr. 7
PE	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	2, 4, 15 mths	15 mths (dose #2)		12 mths	12 mths	Gr. 9		2, 4, 6, 18 mths	6-59 mths	Females Gr. 6	2, 4 mths as per product dosing
NL	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	In 2012 Gr. 6	12, 18 mths	12 mths		12 mths	Catch-up Gr. 4		2, 4, 6, 18 mths	6-23 mths	Females Gr. 6
NT	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	0, 1, 6 mths	12, 18 mths, Post secondary students attending schools outside NT	12 mths; Catch-up <5 yrs		2, 12 mths; Catch-up <5 yrs, Gr. 9	Post secondary students attending schools outside NT		2, 4, 6, 18 mths	≥ 6 mths	Females Gr. 4; Catch-up Gr. 9-12 2009-14
YT	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9	2, 4, 12 mths; Catch-up ≤ 19 yrs	12, 18 mths	12 mths; Catch-up 4-6 yrs		2, 12 mths; Catch-up Gr. 6, post-secondary students not previously immunized			2, 4, (6 HR), 12 mths 3+1 doses	> 6mths	Females Gr. 6; Free to females 9-26 yrs; Available for males 9-26 at cost
NU	2, 4, 6, 18 mths	4-6 yrs	Tdap, Gr. 9 (14-16 yrs)	0, 1, 9 mths	12, 18 mths; Catch-up Gr. 12	15 mths		12 mths; Catch-up Gr. 9 (14-16 yrs)			2, 4, 6, 15 mths	Universal ≥ 6 mths	Females Gr. 6 (≥ 9 yrs)